GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Common Stock

ANL (Adlai Nortye) Common Stock : $0.01 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Common Stock?

Adlai Nortye's quarterly common stock increased from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($0.01 Mil) but then stayed the same from Dec. 2023 ($0.01 Mil) to Jun. 2024 ($0.01 Mil).

Adlai Nortye's annual common stock stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.01 Mil).

Adlai Nortye Common Stock Historical Data

The historical data trend for Adlai Nortye's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye Common Stock Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
Common Stock
- - 0.01

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial - - - 0.01 0.01

Adlai Nortye Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Adlai Nortye Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Common Stock
Comparable Companies
ABOS IVVD CLSD MNOV AVTE ACRV NTRB EPIX IGMS DOMH VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Website
https://www.adlainortye.com
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.